ARTHUR-D.-LITTLE
15.3.2022 10:02:08 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced the promotion of nine of its consultants to the rank of Partner across a number of its global offices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005634/en/
Each new Partner has demonstrated their commitment to ADL, passion and dedication to the industries and clients they serve, and best-in-class experience and expertise. ADL credits a lot of its ongoing growth and success to the development, promotion and retention of its internal talent, with a recent survey on Vault acknowledging these values for setting ADL apart as an employer.
The latest promotions to Partner are as follows:
- Ryan Alnesayan, Partner, Public Services Practice, Riyadh. Leading ADL Riyadh’s office, Ryan has over 14 years of consulting and business advisory experience in strategic planning, economic development, and large-scale transformation projects, with a focus on Saudi Arabia.
- Marcus Beard, Partner, Risk Practice, Cambridge. Marcus’ area of expertise is risk management, in which he primarily focuses on developing next-generation risk management approaches, culture assessment, safety and risk governance and assurance, risk analysis, and executive leadership training, with deep industry experience in travel & transportation.
- Dr. Engin Beken, Partner, Operations Management Practice, Frankfurt & Vienna. Engin is a key expert in strategic performance improvement and digitalization. He is a strong contributor to ADL’s global operations management practice and works with our clients globally, especially in asset-heavy industries.
- Florence Carlot, Partner, Energy & Utilities Practice, Brussels. Florence focuses on strategy and organization in the energy & utilities industry. She has been working within the European energy and utilities sector for over 15 years, enabling large operational and strategic change initiatives across the energy value chain.
- Julien Duvaud-Schelnast, Partner, Telecommunications, Information Technology, Media & Electronics (TIME) Practice, Paris & Stockholm. Operating in both France and Sweden, Julien is an expert on trending topics within the TIME practice, including infrastructure, private networks and sustainability.
- Dr. Michael Eiden, Partner, Technology & Innovation Practice, London. Michael is the Global Head of Artificial Intelligence and Machine Learning at ADL. He is an industry expert with more than 20 years of hands-on experience in designing, developing and commercializing AI solutions in different industries.
- Ben Enejo, Partner, Healthcare & Life Sciences Practice, Boston. Ben is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration; R&D transformation, including advanced technology application, increasing success for rare-disease drug development and launch; patient and drug safety; and quality and compliance excellence.
- Mitsuhiro Henry Umebayashi, Partner, Strategy & Organization Practice, Singapore. Henry leads the S&O practice in South-East Asia and supports clients from multiple industries, such as consumer goods, energy & utilities, infrastructure and healthcare. His main focus is supporting clients with business transformation and growth acceleration arising from management challenges such as sustainability, globalization and digitalization.
- Arjun Vir Singh, Partner, Financial Services Practice, Dubai. Arjun joined ADL in 2020 as the Head of Financial Services for the Middle East region. Actively engaged with fintech, payments, and digital banking, as well as the wider start-up ecosystem across the Middle East region and beyond, Arjun has deep sectorial knowledge. He has launched and managed a payments and fintech business for a large conglomerate across multiple markets in the Middle East and SEA region.
Ignacio Garcia Alves, Chairman and Chief Executive Officer of Arthur D. Little , comments: “I would like to congratulate our nine new Partners, who have worked hard and smart to become true entrepreneurs. Each promotion is richly deserved, and we are extremely grateful for the role they have played in the firm. At ADL we place tremendous value on our people. These nine colleagues have shown they are ready for the next step of their careers, and we are truly excited as they enter into their era of partnership.”
About Arthur D. Little
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.
Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.
For further information, please visit www.adlittle.com or www.adl.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005634/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom